Navigation Links
PAREXEL Introduces The Expert Office(TM) -- Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs

BOSTON, Nov. 5 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, announced today that it has established The Expert Office(TM) at PAREXEL. The Expert Office, which provides a single point of contact for clients to more quickly access PAREXEL's comprehensive worldwide expertise, aligns the Company's leading medical, therapeutic area, regulatory, and clinical operations experts with their counterparts at biopharmaceutical companies. The Expert Office supports PAREXEL in delivering a new level of strategic partnering based on program design expertise, operational excellence, and project leadership.

"Biopharmaceutical companies face myriad regulatory, medical, and scientific issues that are changing the clinical development environment, and PAREXEL is committed to easing these challenges for our customers. The Expert Office has been designed to provide customers with access to a global team of experts who work closely with them to develop customized strategies and oversee the optimal execution of trials. The Expert Office signals a truly new level of strategic partnering between PAREXEL and our customers," said Mark A. Goldberg, M.D., Chief Operating Officer, PAREXEL International.

The Expert Office is comprised of top specialists in their fields, many of whom are former regulators, pharmaceutical company executives, and leaders of medical institutes, who draw on in-depth regulatory, business, and scientific experience. They address a spectrum of issues that may impact critical areas for customers such as study design, safety, patient recruitment, pricing, reimbursement, compliance, and approval. The team's expertise spans Phase I - Phase IV clinical research and a broad range of therapeutic areas, including but not limited to oncology, cardiology, neurology, rheumatology, and infectious disease. The Expert Office draws upon the resources of PAREXEL's experts worldwide as well as an external network of scientific advisors matched with the specific needs of each PAREXEL customer. These experts are integrated into PAREXEL's Clinical Research Services offerings as part of study teams.

"Customers are increasingly looking to PAREXEL to provide insightful strategic guidance related to their compounds in development," said Udo Kiessling, M.D., Corporate Vice President and Chief Medical Officer, who heads The Expert Office at PAREXEL. "Our thought leaders form a comprehensive, cohesive team that provides a strong relationship among medical practice, regulatory affairs, and clinical operations across a broad range of therapeutic areas. This consolidation of knowledge throughout the lifecycle of a program is focused on helping biopharmaceutical companies make faster, better informed development and commercialization decisions and accelerate clinical research."

The Expert Office at PAREXEL offers capabilities such as:

  • Creation of development plans aimed at successful marketing authorizations and launch
  • Product class assessments and deep medical insight for specific indications and multi-therapeutic areas
  • Protocol review to identify gaps that may delay development
  • Feasibility and patient recruitment guidance aimed at acceleration of study start-up
  • Insight into regulatory guidelines and management of successful regulatory interactions

PAREXEL draws on the breadth and depth of its expertise to help customers optimize development and increase global market access. For more information about The Expert Office at PAREXEL visit:

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has over 9,130 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended June 30, 2009 as filed with the SEC on August 28, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

    Jennifer Baird,                         Gene Carozza/Kim Baker
    Senior Director of Public Relations
    PAREXEL International                   PAN Communications
    Tel: +781-434-4409                      Tel: +978-474-1900
    Email:       Email:

SOURCE PAREXEL International Corporation

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PAREXEL Experts to Present Leading Insights at Drug Information Association Annual Clinical Forum
2. PAREXEL Announces Date of First Quarter Fiscal Year 2010 Earnings Release and Conference Call
3. PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results
4. PAREXEL Enhances Study Start-Up and Recruitment Capabilities With Appointment of Dr. Lars-Olof Eriksson, Formerly With Merck
5. PAREXEL International to Present at Goldman Sachs Annual Global Healthcare Conference and the Jefferies Annual Healthcare Conference
6. PAREXEL Experts to Address Partnering Best Practices and Innovative Trial Design at Partnerships With CROs Conference
7. PAREXEL Announces Date of Third Quarter Fiscal Year 2009 Earnings Release and Conference Call
8. PAREXEL International to Present at Raymond James 30th Annual Institutional Investors and the Barclays Capital Global Healthcare Conferences
9. PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil
10. PAREXEL Reports Second Quarter Fiscal Year 2009 Financial Results
11. PAREXEL Announces Date of Second Quarter Fiscal Year 2009 Earnings Release and Conference Call
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... Next IT Healthcare, the leader in patient ... year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher of ... the category of Digital Solutions for its innovative, industry-leading product, Alme Health Coach. ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Lutronic, a ... of Clarity, the latest addition to the devices for sale in the United States. ... nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... SACC-GA and SACC-USA through membership and leadership since 2008. Gary Bruce, President ... SACC-USA . Gary has spent a significant amount of time in Sweden ...
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., ... largest order to date. , The order will be from the China Disabled ... Cochlear Implant System is an effective solution for children and adults suffering from ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Sensor Networks, a leader in intelligent sensors and analytic software for sensor network-based systems, announced ... data collection of vital signs. Photo - ... ... ... ...
(Date:12/1/2015)... , Dec. 1, 2015 Ampio Pharmaceuticals, ... York Stock Exchange has established January 5, 2016 as the ... stockholders of the shares of Common Stock of Aytu ... share of Aytu common stock for every five (5) ... record date, December 1, 2015. The distribution date will be ...
(Date:12/1/2015)... Sweden , December 1, 2015 ... International Breast Cancer Study Group (IBCSG, Bern ... ) to be part of a state of the ... cancer drug.  --> --> ... cancer being treated with anti-hormonal therapy in combination with palbociclib, ...
Breaking Medicine Technology: